ATP drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (16)
Papers in which this entity is mentioned.
- Chromosomal instability as a driver of cancer progression. (2025)
- MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. (2025)
- Sequence modeling and design from molecular to genome scale with Evo. (2024)
- ENPP1 Immunobiology as a Therapeutic Target. (2023)
- RNA splicing dysregulation and the hallmarks of cancer. (2023)
- Nanopore sequencing of RNA and cDNA molecules in . (2022)
- Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. (2022)
- Transcriptomic analyses of gastrulation-stage mouse embryos with differential susceptibility to alcohol. (2021)
- Accurate detection of circulating tumor DNA using nanopore consensus sequencing. (2021)
- HSP70 and HSP90 in neurodegenerative diseases. (2020)
- Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways. (2019)
- Maternal circulating miRNAs that predict infant FASD outcomes influence placental maturation. (2019)
- Picky comprehensively detects high-resolution structural variants in nanopore long reads. (2018)
- Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. (2016)
- Three decades of nanopore sequencing. (2016)
- A germline polymorphism of thymine DNA glycosylase induces genomic instability and cellular transformation. (2014)
Merged raw entities (5)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| atp | drug | 63 | 97 |
| adenine triphosphate | drug | — | — |
| epicentre atp | drug | — | — |
| illumina atp | drug | — | — |
| unlabeled atp | drug | — | — |